Zentrum für Neuropathologie und Prionforschung
print

Sprachumschaltung

Navigationspfad


Inhaltsbereich

Professor Dr. med. Patrick Harter

[2024] [2023] [2022] [2021] [2020] [2019] [2018] [2017] [2016] [2015] [2014] [2013] [2012] [2011] [2010] [2009] [2007]

2024

Eckhardt A, Drexler R, Schoof M, Struve N, Capper D, Jelgersma C, Onken J, Harter PN, Weber KJ, Divé I, Rothkamm K, Hoffer K, Klumpp L, Ganser K, Petersen C, Ricklefs F, Kriegs M & Schüller U
Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma.
Neuro-oncology, 2024 Mar 04, 26 (3) 503-513

2023

Bode H, Kresbach C, Holdhof D, Dorostkar MM, Harter PN, Hench J, Frank S, Suwala AK, Schweizer L, Eckhardt A, Neyazi S, Bockmayr M, Wefers AK & Schüller U
Molecular refinement of pilocytic astrocytoma in adult patients.
Neuropathology and applied neurobiology, 2023 Dec 19, e12949

Mann L, Rosenow F, Strzelczyk A, Hattingen E, Willems LM, Harter PN, Weber K & Mann C
The impact of referring patients with drug-resistant focal epilepsy to an epilepsy center for presurgical diagnosis.
Neurological research and practice, 2023 Dec 14, 5 (1) 65

Schmid K, Sehring J, Németh A, Harter PN, Weber KJ, Vengadeswaran A, Storf H, Seidemann C, Karki K, Fischer P, Dohmen H, Selignow C, von Deimling A, Grau S, Schröder U, Plate KH, Stein M, Uhl E, Acker T & Amsel D
DistSNE: Distributed computing and online visualization of DNA methylation-based central nervous system tumor classification.
Brain pathology (Zurich, Switzerland), 2023 Nov 27, e13228

Burger MC, Forster MT, Romanski A, Straßheimer F, Macas J, Zeiner PS, Steidl E, Herkt S, Weber KJ, Schupp J, Lun JH, Strecker MI, Wlotzka K, Cakmak P, Opitz C, George R, Mildenberger IC, Nowakowska P, Zhang C, Röder J, Müller E, Ihrig K, Langen KJ, Rieger MA, Herrmann E, Bonig H, Harter PN, Reiss Y, Hattingen E, Rödel F, Plate KH, Tonn T, Senft C, Steinbach JP & Wels WS
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
Neuro-oncology, 2023 Nov 02, 25 (11) 2058-2071

Karschnia P, Smits M, Reifenberger G, Le Rhun E, Ellingson BM, Galldiks N, Kim MM, Huse JT, Schnell O, Harter PN, Mohme M, Expert Rater Panel, von Baumgarten L, Albert NL, Huang RY, Mehta MP, van den Bent M, Weller M, Vogelbaum MA, Chang SM, Berger MS & Tonn JC
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups.
The Lancet. Oncology, 2023 Nov, 24 (11) e438-e450

Drexler R, Khatri R, Sauvigny T, Mohme M, Maire CL, Ryba A, Zghaibeh Y, Dührsen L, Salviano-Silva A, Lamszus K, Westphal M, Gempt J, Wefers AK, Neumann J, Bode H, Hausmann F, Huber TB, Bonn S, Jütten K, Delev D, Weber KJ, Harter PN, Onken J, Vajkoczy P, Capper D, Wiestler B, Weller M, Snijder B, Buck A, Weiss T, Keough MB, Ni L, Monje M, Silverbush D, Hovestadt V, Suvà ML, Krishna S, Hervey-Jumper SL, Schüller U, Heiland DH, Hänzelmann S & Ricklefs FL
Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerability.
bioRxiv : the preprint server for biology, 2023 Aug 07

Haake M, Haack B, Schäfer T, Harter PN, Mattavelli G, Eiring P, Vashist N, Wedekink F, Genssler S, Fischer B, Dahlhoff J, Mokhtari F, Kuzkina A, Welters MJP, Benz TM, Sorger L, Thiemann V, Almanzar G, Selle M, Thein K, Späth J, Gonzalez MC, Reitinger C, Ipsen-Escobedo A, Wistuba-Hamprecht K, Eichler K, Filipski K, Zeiner PS, Beschorner R, Goedemans R, Gogolla FH, Hackl H, Rooswinkel RW, Thiem A, Roche PR, Joshi H, Pühringer D, Wöckel A, Diessner JE, Rüdiger M, Leo E, Cheng PF, Levesque MP, Goebeler M, Sauer M, Nimmerjahn F, Schuberth-Wagner C, von Felten S, Mittelbronn M, Mehling M, Beilhack A, van der Burg SH, Riedel A, Weide B, Dummer R & Wischhusen J
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.
Nature communications, 2023 Jul 20, 14 (1) 4253

Weller J, Katzendobler S, Niedermeyer S, Harter PN, Herms J, Trumm C, Niyazi M, Thon N, Tonn JC & Stoecklein VM
Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status.
Journal of neuro-oncology, 2023 Jun, 163 (2) 407-415

Hoffmann L, Coras R, Kobow K, López-Rivera JA, Lal D, Leu C, Najm I, Nürnberg P, Herms J, Harter PN, Bien CG, Kalbhenn T, Müller M, Pieper T, Hartlieb T, Kudernatsch M, Hamer H, Brandner S, Rössler K, Blümcke I & Jabari S
Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes.
Acta neuropathologica, 2023 Jun, 145 (6) 815-827

Hoffmann L, Coras R, Kobow K, López-Rivera JA, Lal D, Leu C, Najm I, Nürnberg P, Herms J, Harter PN, Bien CG, Kalbhenn T, Müller M, Pieper T, Hartlieb T, Kudernatsch M, Hamer H, Brandner S, Rössler K, Blümcke I & Jabari S
Correction to: Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes.
Acta neuropathologica, 2023 Jun, 145 (6) 851-855

Spitzer D, Khel MI, Pütz T, Zinke J, Jia X, Sommer K, Filipski K, Thorsen F, Freiman TM, Günther S, Plate KH, Harter PN, Liebner S, Reiss Y, Di Tacchio M, Guérit S & Devraj K
A flow cytometry-based protocol for syngenic isolation of neurovascular unit cells from mouse and human tissues.
Nature protocols, 2023 May, 18 (5) 1510-1542

Harter PN, Weber KJ & Ronellenfitsch MW
[Histological and molecular characteristics of tumours of the peripheral nervous system].
Pathologie (Heidelberg, Germany), 2023 May, 44 (3) 197-208

Teske N, Chiquillo-Domínguez M, Skrap B, Harter PN, Rejeski K, Blobner J, von Baumgarten L, Tonn JC, Kunz M, Thon N & Karschnia P
Shunt dependency in supratentorial intraventricular tumors depends on the extent of tumor resection.
Acta neurochirurgica, 2023 Apr, 165 (4) 1053-1064

Friedauer L, Foerch C, Steinbach J, Hattingen E, Harter PN, Armbrust M, Urban H, Steidl E, Neuhaus E & von Brauchitsch S
The Acute Superficial Siderosis Syndrome - Clinical Entity, Imaging Findings, and Histopathology.
Cerebellum (London, England), 2023 Apr, 22 (2) 296-304

Drexler R, Schüller U, Eckhardt A, Filipski K, Hartung TI, Harter PN, Divé I, Forster MT, Czabanka M, Jelgersma C, Onken J, Vajkoczy P, Capper D, Siewert C, Sauvigny T, Lamszus K, Westphal M, Dührsen L & Ricklefs FL
DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
Neuro-oncology, 2023 Feb 14, 25 (2) 315-325

Schweizer L, Seegerer P, Kim HY, Saitenmacher R, Muench A, Barnick L, Osterloh A, Dittmayer C, Jödicke R, Pehl D, Reinhardt A, Ruprecht K, Stenzel W, Wefers AK, Harter PN, Schüller U, Heppner FL, Alber M, Müller KR & Klauschen F
Analysing cerebrospinal fluid with explainable deep learning: From diagnostics to insights.
Neuropathology and applied neurobiology, 2023 Feb, 49 (1) e12866

Kiyose M, Herrmann E, Roesler J, Zeiner PS, Steinbach JP, Forster MT, Plate KH, Czabanka M, Vogl TJ, Hattingen E, Mittelbronn M, Breuer S, Harter PN & Bernatz S
MR imaging profile and histopathological characteristics of tumour vasculature, cell density and proliferation rate define two distinct growth patterns of human brain metastases from lung cancer.
Neuroradiology, 2023 Feb, 65 (2) 275-285

Gretser S, Weber KJ, Braun Y, Harter PN, Rolle U, McNally J & Gradhand E
Tissue Shrinkage of Resected Specimens in Hirschsprung's Disease: Why Pediatric Surgeons Think the Bowel Specimen was Longer Than Indicated in the Pathology Report.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, 2023, 26 (3) 287-291

Divé I, Weber KJ, Hartung TI, Steidl E, Wagner M, Hattingen E, Franz K, Fokas E, Ronellenfitsch MW, Herrlinger U, Harter PN & Steinbach JP
Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma.
Neuro-oncology advances, 2023, 5 (1) vdad131

Proestler E, Donzelli J, Nevermann S, Breitwieser K, Koch LF, Best T, Fauth M, Wickström M, Harter PN, Kogner P, Lavieu G, Larsson K & Saul MJ
The multiple functions of miR-574-5p in the neuroblastoma tumor microenvironment.
Frontiers in pharmacology, 2023, 14 1183720

Blobner J, Dengler L, Blobner S, Eberle C, Weller J, Teske N, Karschnia P, Rühlmann K, Heinrich K, Ziemann F, Greif PA, Jeremias I, Wuerstlein R, Hasselmann K, Dorostkar M, Harter PN, Quach S, Stoecklein V, Albert NL, Niyazi M, Tonn JC, Thon N, Christoph Westphalen B & von Baumgarten L
Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma.
Neuro-oncology advances, 2023, 5 (1) vdad060

2022

Key J, Gispert S, Koornneef L, Sleddens-Linkels E, Kohli A, Torres-Odio S, Koepf G, Amr S, Reichlmeir M, Harter PN, West AP, Münch C, Baarends WM & Auburger G
CLPP Depletion Causes Diplotene Arrest; Underlying Testis Mitochondrial Dysfunction Occurs with Accumulation of Perrault Proteins ERAL1, PEO1, and HARS2.
Cells, 2022 Dec 22, 12 (1)

Spitzer D, Puetz T, Armbrust M, Dunst M, Macas J, Croll F, Plate KH, Reiss Y, Liebner S, Harter PN, Guérit S & Devraj K
Anti-osteopontin therapy leads to improved edema and infarct size in a murine model of ischemic stroke.
Scientific reports, 2022 Dec 03, 12 (1) 20925

Felix M, Friedel D, Jayavelu AK, Filipski K, Reinhardt A, Warnken U, Stichel D, Schrimpf D, Korshunov A, Wang Y, Kessler T, Etminan N, Unterberg A, Herold-Mende C, Heikaus L, Sahm F, Wick W, Harter PN, von Deimling A & Reuss DE
HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
Neuro-oncology, 2022 Dec 01, 24 (12) 2121-2132

Jurmeister P, Glöß S, Roller R, Leitheiser M, Schmid S, Mochmann LH, Payá Capilla E, Fritz R, Dittmayer C, Friedrich C, Thieme A, Keyl P, Jarosch A, Schallenberg S, Bläker H, Hoffmann I, Vollbrecht C, Lehmann A, Hummel M, Heim D, Haji M, Harter P, Englert B, Frank S, Hench J, Paulus W, Hasselblatt M, Hartmann W, Dohmen H, Keber U, Jank P, Denkert C, Stadelmann C, Bremmer F, Richter A, Wefers A, Ribbat-Idel J, Perner S, Idel C, Chiariotti L, Della Monica R, Marinelli A, Schüller U, Bockmayr M, Liu J, Lund VJ, Forster M, Lechner M, Lorenzo-Guerra SL, Hermsen M, Johann PD, Agaimy A, Seegerer P, Koch A, Heppner F, Pfister SM, Jones DTW, Sill M, von Deimling A, Snuderl M, Müller KR, Forgó E, Howitt BE, Mertins P, Klauschen F & Capper D
DNA methylation-based classification of sinonasal tumors.
Nature communications, 2022 Nov 28, 13 (1) 7148

Luger AL, König S, Samp PF, Urban H, Divé I, Burger MC, Voss M, Franz K, Fokas E, Filipski K, Demes MC, Stenzinger A, Sahm F, Reuss DE, Harter PN, Wagner S, Hattingen E, Wichert J, Lapa C, Fröhling S, Steinbach JP & Ronellenfitsch MW
Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.
Journal of neuro-oncology, 2022 Sep, 159 (2) 243-259

Spitzer D, Guérit S, Puetz T, Khel MI, Armbrust M, Dunst M, Macas J, Zinke J, Devraj G, Jia X, Croll F, Sommer K, Filipski K, Freiman TM, Looso M, Günther S, Di Tacchio M, Plate KH, Reiss Y, Liebner S, Harter PN & Devraj K
Profiling the neurovascular unit unveils detrimental effects of osteopontin on the blood-brain barrier in acute ischemic stroke.
Acta neuropathologica, 2022 Aug, 144 (2) 305-337

Zeiner PS, Filipski K, Filmann N, Forster MT, Voss M, Fokas E, Herrlinger U, Harter PN, Steinbach JP & Ronellenfitsch MW
Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma.
Neurology, 2022 May 17, 98 (20) e2073-e2083

Zeiner PS, Mann L, Filipski K, Starzetz T, Forster MT, Ronellenfitsch MW, Steinbach JP, Mittelbronn M, Wagner M & Harter PN
Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy.
European journal of neurology, 2022 Feb, 29 (2) 543-554

Tehranian C, Fankhauser L, Harter PN, Ratcliffe CDH, Zeiner PS, Messmer JM, Hoffmann DC, Frey K, Westphal D, Ronellenfitsch MW, Sahai E, Wick W, Karreman MA & Winkler F
The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.
Neuro-oncology, 2022 Feb 01, 24 (2) 213-225

Voss M, Wenger KJ, von Mettenheim N, Bojunga J, Vetter M, Diehl B, Franz K, Gerlach R, Ronellenfitsch MW, Harter PN, Hattingen E, Steinbach JP, Rödel C & Rieger J
Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial.
European journal of nutrition, 2022 Feb, 61 (1) 477-487

Ebrahimi A, Korshunov A, Reifenberger G, Capper D, Felsberg J, Trisolini E, Pollo B, Calatozzolo C, Prinz M, Staszewski O, Schweizer L, Schittenhelm J, Harter PN, Paulus W, Thomas C, Kohlhof-Meinecke P, Seiz-Rosenhagen M, Milde T, Casalini BM, Suwala A, Wefers AK, Reinhardt A, Sievers P, Kramm CM, Etminam N, Unterberg A, Wick W, Herold-Mende C, Sturm D, Pfister SM, Sill M, Jones DTW, Schrimpf D, Reuss DE, Aldape K, Abdullaev Z, Sahm F, von Deimling A & Stichel D
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.
Acta neuropathologica communications, 2022 Jan 10, 10 (1) 5

2021

Schmid S, Solomon DA, Perez E, Thieme A, Kleinschmidt-DeMasters BK, Giannini C, Reinhardt A, Asa SL, Mete O, Stichel D, Siewert C, Dittmayer C, Hasselblatt M, Paulus W, Nagel C, Harter PN, Schittenhelm J, Honegger J, Rushing E, Coras R, Pfister SM, Buslei R, Koch A, Perry A, Jones DTW, von Deimling A, Capper D & Lopes MB
Genetic and epigenetic characterization of posterior pituitary tumors.
Acta neuropathologica, 2021 Dec, 142 (6) 1025-1043

Maas SLN, Stichel D, Hielscher T, Sievers P, Berghoff AS, Schrimpf D, Sill M, Euskirchen P, Blume C, Patel A, Dogan H, Reuss D, Dohmen H, Stein M, Reinhardt A, Suwala AK, Wefers AK, Baumgarten P, Ricklefs F, Rushing EJ, Bewerunge-Hudler M, Ketter R, Schittenhelm J, Jaunmuktane Z, Leu S, Greenway FEA, Bridges LR, Jones T, Grady C, Serrano J, Golfinos J, Sen C, Mawrin C, Jungk C, Hänggi D, Westphal M, Lamszus K, Etminan N, Jungwirth G, Herold-Mende C, Unterberg A, Harter PN, Wirsching HG, Neidert MC, Ratliff M, Platten M, Snuderl M, Aldape KD, Brandner S, Hench J, Frank S, Pfister SM, Jones DTW, Reifenberger G, Acker T, Wick W, Weller M, Preusser M, von Deimling A, Sahm F & German Consortium on Aggressive Meningiomas (KAM)
Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021 Dec 01, 39 (34) 3839-3852

Tirado-Gonzalez I, Descot A, Soetopo D, Nevmerzhitskaya A, Schäffer A, Kur IM, Czlonka E, Wachtel C, Tsoukala I, Müller L, Schäfer AL, Weitmann M, Dinse P, Alberto E, Buck MC, Landry JJ, Baying B, Slotta-Huspenina J, Roesler J, Harter PN, Kubasch AS, Meinel J, Elwakeel E, Strack E, Quang CT, Abdel-Wahab O, Schmitz M, Weigert A, Schmid T, Platzbecker U, Benes V, Ghysdael J, Bonig H, Götze KS, Rothlin CV, Ghosh S & Medyouf H
AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia.
Cancer discovery, 2021 Nov, 11 (11) 2924-2943

Sievers P, Henneken SC, Blume C, Sill M, Schrimpf D, Stichel D, Okonechnikov K, Reuss DE, Benzel J, Maaß KK, Kool M, Sturm D, Zheng T, Ghasemi DR, Kohlhof-Meinecke P, Cruz O, Suñol M, Lavarino C, Ruf V, Boldt HB, Pagès M, Pouget C, Schweizer L, Kranendonk MEG, Akhtar N, Bunkowski S, Stadelmann C, Schüller U, Mueller WC, Dohmen H, Acker T, Harter PN, Mawrin C, Beschorner R, Brandner S, Snuderl M, Abdullaev Z, Aldape K, Gilbert MR, Armstrong TS, Ellison DW, Capper D, Ichimura K, Reifenberger G, Grundy RG, Jabado N, Krskova L, Zapotocky M, Vicha A, Varlet P, Wesseling P, Rutkowski S, Korshunov A, Wick W, Pfister SM, Jones DTW, von Deimling A, Pajtler KW & Sahm F
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors.
Acta neuropathologica, 2021 Nov, 142 (5) 827-839

Klemm F, Möckl A, Salamero-Boix A, Alekseeva T, Schäffer A, Schulz M, Niesel K, Maas RR, Groth M, Elie BT, Bowman RL, Hegi ME, Daniel RT, Zeiner PS, Zinke J, Harter PN, Plate KH, Joyce JA & Sevenich L
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis.
Nature cancer, 2021 Oct, 2 (10) 1086-1101

Wirsik NM, Ehlers J, Mäder L, Ilina EI, Blank AE, Grote A, Feuerhake F, Baumgarten P, Devraj K, Harter PN, Mittelbronn M & Naumann U
TGF-β activates pericytes via induction of the epithelial-to-mesenchymal transition protein SLUG in glioblastoma.
Neuropathology and applied neurobiology, 2021 Oct, 47 (6) 768-780

Verkuijl SJ, Friedmacher F, Harter PN, Rolle U & Broens PM
Persistent bowel dysfunction after surgery for Hirschsprung's disease: A neuropathological perspective.
World journal of gastrointestinal surgery, 2021 Aug 27, 13 (8) 822-833

Maurer GD, Tichy J, Harter PN, Nöth U, Weise L, Quick-Weller J, Deichmann R, Steinbach JP, Bähr O & Hattingen E
Matching Quantitative MRI Parameters with Histological Features of Treatment-Naïve IDH Wild-Type Glioma.
Cancers, 2021 Aug 12, 13 (16)

Steidl E, Filipski K, Zeiner PS, Wagner M, Fokas E, Forster MT, Ronellenfitsch MW, Divé I, Steinbach JP, Harter PN & Bähr O
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Journal of cancer research and clinical oncology, 2021 Aug, 147 (8) 2373-2383

Neef V, König S, Monden D, Dubinski D, Benesch A, Raimann FJ, Piekarski F, Ronellenfitsch MW, Harter PN, Senft C, Meybohm P, Hattingen E, Zacharowski K, Seifert V & Baumgarten P
Clinical Outcome and Risk Factors of Red Blood Cell Transfusion in Patients Undergoing Elective Primary Meningioma Resection.
Cancers, 2021 Jul 18, 13 (14)

Filipski K, Scherer M, Zeiner KN, Bucher A, Kleemann J, Jurmeister P, Hartung TI, Meissner M, Plate KH, Fenton TR, Walter J, Tierling S, Schilling B, Zeiner PS & Harter PN
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma.
Journal for immunotherapy of cancer, 2021 Jul, 9 (7)

Suwala AK, Stichel D, Schrimpf D, Maas SLN, Sill M, Dohmen H, Banan R, Reinhardt A, Sievers P, Hinz F, Blattner-Johnson M, Hartmann C, Schweizer L, Boldt HB, Kristensen BW, Schittenhelm J, Wood MD, Chotard G, Bjergvig R, Das A, Tabori U, Hasselblatt M, Korshunov A, Abdullaev Z, Quezado M, Aldape K, Harter PN, Snuderl M, Hench J, Frank S, Acker T, Brandner S, Winkler F, Wesseling P, Pfister SM, Reuss DE, Wick W, von Deimling A, Jones DTW & Sahm F
Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
Acta neuropathologica, 2021 Jul, 142 (1) 179-189

Loreth D, Schuette M, Zinke J, Mohme M, Piffko A, Schneegans S, Stadler J, Janning M, Loges S, Joosse SA, Lamszus K, Westphal M, Müller V, Glatzel M, Matschke J, Gebhardt C, Schneider SW, Belczacka I, Volkmer B, Greinert R, Yaspo ML, Harter PN, Pantel K & Wikman H
CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis.
International journal of molecular sciences, 2021 Jun 29, 22 (13)

Thomas C, Thierfelder F, Träger M, Soschinski P, Müther M, Edelmann D, Förster A, Geiler C, Kim HY, Filipski K, Harter PN, Schittenhelm J, Eckert F, Ntoulias G, May SA, Stummer W, Onken J, Vajkoczy P, Schüller U, Heppner FL, Capper D, Koch A, Kaul D, Paulus W, Hasselblatt M & Schweizer L
TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Acta neuropathologica, 2021 Jun, 141 (6) 959-970

Monden D, Raimann FJ, Neef V, Dubinski D, Gessler F, Keil F, Forster MT, Ronellenfitsch MW, Harter PN, Freiman TM, Hattingen E, Seifert V, Senft C & Baumgarten P
Meningioma Surgery in Patients ≥70 Years of Age: Clinical Outcome and Validation of the SKALE Score.
Journal of clinical medicine, 2021 Apr 22, 10 (9)

Bernatz S, Monden D, Gessler F, Radic T, Hattingen E, Senft C, Seifert V, Ronellenfitsch MW, Plate KH, Harter PN & Baumgarten P
Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients.
Journal of molecular histology, 2021 Apr, 52 (2) 233-243

Braun Y, Filipski K, Bernatz S, Baumgarten P, Roller B, Zinke J, Zeiner PS, Ilina E, Senft C, Ronellenfitsch MW, Plate KH, Bähr O, Hattingen E, Steinbach JP, Mittelbronn M & Harter PN
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.
Neuropathology and applied neurobiology, 2021 Apr, 47 (3) 379-393

Mann C, Conradi N, Freiman TM, Spyrantis A, Konczalla J, Hattingen E, Wagner M, Harter PN, Mueller M, Leyer AC, Reif PS, Bauer S, Schubert-Bast S, Strzelczyk A & Rosenow F
Postoperative outcomes and surgical ratio at a newly established epilepsy center: The first 100 procedures.
Epilepsy & behavior : E&B, 2021 Mar, 116 107715

Sievers P, Sill M, Schrimpf D, Stichel D, Reuss DE, Sturm D, Hench J, Frank S, Krskova L, Vicha A, Zapotocky M, Bison B, Castel D, Grill J, Debily MA, Harter PN, Snuderl M, Kramm CM, Reifenberger G, Korshunov A, Jabado N, Wesseling P, Wick W, Solomon DA, Perry A, Jacques TS, Jones C, Witt O, Pfister SM, von Deimling A, Jones DTW & Sahm F
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.
Neuro-oncology, 2021 Jan 30, 23 (1) 34-43

Baumgarten P, Sarlak M, Monden D, Spyrantis A, Bernatz S, Gessler F, Dubinski D, Hattingen E, Marquardt G, Strzelczyk A, Rosenow F, Harter PN, Seifert V & Freiman TM
Early and Late Postoperative Seizures in Meningioma Patients and Prediction by a Recent Scoring System.
Cancers, 2021 Jan 25, 13 (3)

Lauer M, Lauer A, You SJ, Kluge S, Hattingen E, Harter PN, Senft C, Wagner M & Voss M
Neurotoxicity of subarachnoid Gd-based contrast agent accumulation: a potential complication of intraoperative MRI?
Neurosurgical focus, 2021 Jan, 50 (1) E12

Dubinski D, Won SY, Rauch M, Behmanesh B, Ngassam LDC, Baumgarten P, Senft C, Harter PN, Bernstock JD, Freiman TM, Seifert V & Gessler F
Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma.
Frontiers in immunology, 2021, 12 627650

Divé I, Steidl E, Wagner M, Filipski K, Burger MC, Franz K, Harter PN, Bähr O, Fokas E, Herrlinger U & Steinbach JP
Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas.
Oncology, 2021, 99 (4) 215-224

2020

Bernatz S, Ackermann J, Mandel P, Kaltenbach B, Zhdanovich Y, Harter PN, Döring C, Hammerstingl R, Bodelle B, Smith K, Bucher A, Albrecht M, Rosbach N, Basten L, Yel I, Wenzel M, Bankov K, Koch I, Chun FK, Köllermann J, Wild PJ & Vogl TJ
Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features.
European radiology, 2020 Dec, 30 (12) 6757-6769

Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS, Saleem U, Hansen A, Luxán G, Günther S, Pham MD, Krishnan J, Harter PN, Ermel UH, Frangakis AS, Milting H, Zeiher AM, Klingel K, Cinatl J, Dendorfer A, Eschenhagen T, Tschöpe C, Ciesek S & Dimmeler S
SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes.
Cardiovascular research, 2020 Dec 01, 116 (14) 2207-2215

Wenger KJ, Wagner M, Harter PN, Franz K, Bojunga J, Fokas E, Imhoff D, Rödel C, Rieger J, Hattingen E, Steinbach JP, Pilatus U & Voss M
Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial.
Cancers, 2020 Nov 27, 12 (12)

Voss M, Wagner M, von Mettenheim N, Harter PN, Wenger KJ, Franz K, Bojunga J, Vetter M, Gerlach R, Glatzel M, Paulsen F, Hattingen E, Baehr O, Ronellenfitsch MW, Fokas E, Imhoff D, Steinbach JP, Rödel C & Rieger J
ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma.
International journal of radiation oncology, biology, physics, 2020 Nov 15, 108 (4) 987-995

Wenger KJ, Richter C, Burger MC, Urban H, Kaulfuss S, Harter PN, Sreeramulu S, Schwalbe H, Steinbach JP, Hattingen E, Bähr O & Pilatus U
Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032.
Cancers, 2020 Oct 29, 12 (11)

Urban H, Maurer GD, Luger AL, Lorenz NI, Sauer B, Stroh C, Trojan J, Mittelbronn M, Steinbach JP, Harter PN & Ronellenfitsch MW
Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer.
Cancers, 2020 Oct 20, 12 (10)

Banan R, Stichel D, Bleck A, Hong B, Lehmann U, Suwala A, Reinhardt A, Schrimpf D, Buslei R, Stadelmann C, Ehlert K, Prinz M, Acker T, Schittenhelm J, Kaul D, Schweizer L, Capper D, Harter PN, Etminan N, Jones DTW, Pfister SM, Herold-Mende C, Wick W, Sahm F, von Deimling A, Hartmann C & Reuss DE
Infratentorial IDH-mutant astrocytoma is a distinct subtype.
Acta neuropathologica, 2020 Oct, 140 (4) 569-581

Sievers P, Hielscher T, Schrimpf D, Stichel D, Reuss DE, Berghoff AS, Neidert MC, Wirsching HG, Mawrin C, Ketter R, Paulus W, Reifenberger G, Lamszus K, Westphal M, Etminan N, Ratliff M, Herold-Mende C, Pfister SM, Jones DTW, Weller M, Harter PN, Wick W, Preusser M, von Deimling A & Sahm F
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.
Acta neuropathologica, 2020 Sep, 140 (3) 409-413

Bohmann FO, Seiler A, Gelhard S, Stolz L, Brill B, Brunkhorst R, Steinmetz H, Harter PN, Mittelbronn M & Foerch C
Blood Pressure Lowering Decreases Intracerebral Hemorrhage Volume and Improves Behavioral Outcomes in Experimental Animals.
Journal of stroke, 2020 Sep, 22 (3) 416-418

Braczynski AK, Gfroerer S, Beschorner R, Harter PN, Baumgarten P, Rolle U & Mittelbronn M
Cholinergic innervation and ganglion cell distribution in Hirschsprung's disease.
BMC pediatrics, 2020 Aug 24, 20 (1) 399

Luger AL, Lorenz NI, Urban H, Divé I, Engel AL, Strassheimer F, Dettmer K, Zeiner PS, Shaid S, Struve N, Kriegs M, Hofmann U, Oefner PJ, Harter PN, Steinbach JP & Ronellenfitsch MW
Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death.
Cancers, 2020 Aug 03, 12 (8)

Key J, Harter PN, Sen NE, Gradhand E, Auburger G & Gispert S
Mid-Gestation lethality of Atxn2l-Ablated Mice.
International journal of molecular sciences, 2020 Jul 20, 21 (14)

Ronellenfitsch MW, Harter PN, Kirchner M, Heining C, Hutter B, Gieldon L, Schittenhelm J, Schuhmann MU, Tatagiba M, Marquardt G, Wagner M, Endris V, Brandts CH, Mautner VF, Schröck E, Weichert W, Brors B, von Deimling A, Mittelbronn M, Steinbach JP, Reuss DE, Glimm H, Stenzinger A & Fröhling S
Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.
The Journal of clinical investigation, 2020 May 01, 130 (5) 2488-2495

Braczynski AK, Capper D, Jones DTW, Schittenhelm J, Stichel D, von Deimling A, Harter PN & Mittelbronn M
High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma.
Pathology, research and practice, 2020 Jan, 216 (1) 152728

2019

Ghasemi DR, Sill M, Okonechnikov K, Korshunov A, Yip S, Schutz PW, Scheie D, Kruse A, Harter PN, Kastelan M, Wagner M, Hartmann C, Benzel J, Maass KK, Khasraw M, Sträter R, Thomas C, Paulus W, Kratz CP, Witt H, Kawauchi D, Herold-Mende C, Sahm F, Brandner S, Kool M, Jones DTW, von Deimling A, Pfister SM, Reuss DE & Pajtler KW
MYCN amplification drives an aggressive form of spinal ependymoma.
Acta neuropathologica, 2019 Dec, 138 (6) 1075-1089

Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Scheel AH, Büttner R, Grauer OM, Schittenhelm J, Tabatabai G, Harter PN, Günther S, Devraj K, Plate KH & Reiss Y
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Cancer immunology research, 2019 Dec, 7 (12) 1910-1927

Zeiner PS, Kinzig M, Divé I, Maurer GD, Filipski K, Harter PN, Senft C, Bähr O, Hattingen E, Steinbach JP, Sörgel F, Voss M, Steidl E & Ronellenfitsch MW
Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.
Journal of clinical medicine, 2019 Nov 21, 8 (12)

Bernatz S, Ilina EI, Devraj K, Harter PN, Mueller K, Kleber S, Braun Y, Penski C, Renner C, Halder R, Jennewein L, Solbach C, Thorsen F, Pestalozzi BC, Mischo A & Mittelbronn M
Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases.
Journal of experimental & clinical cancer research : CR, 2019 Oct 29, 38 (1) 434

Russo A, Paret C, Alt F, Burhenne J, Fresnais M, Wagner W, Glaser M, Bender H, Huprich S, Harter PN, Filipski K, Lehmann N, Backes N, Roth L, Seidmann L, Sommer C, Brockmann MA, Pietsch T, Neu MA, Wingerter A & Faber J
Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor.
International journal of molecular sciences, 2019 Aug 30, 20 (17)

Filipski K, Braun Y, Zinke J, Roller B, Baumgarten P, Wagner M, Senft C, Zeiner PS, Ronellenfitsch MW, Steinbach JP, Plate KH, Gasparoni G, Mittelbronn M, Capper D & Harter PN
Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas.
Acta neuropathologica, 2019 Aug, 138 (2) 331-334

Zeiner PS, Preusse C, Golebiewska A, Zinke J, Iriondo A, Muller A, Kaoma T, Filipski K, Müller-Eschner M, Bernatz S, Blank AE, Baumgarten P, Ilina E, Grote A, Hansmann ML, Verhoff MA, Franz K, Feuerhake F, Steinbach JP, Wischhusen J, Stenzel W, Niclou SP, Harter PN & Mittelbronn M
Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas.
Brain pathology (Zurich, Switzerland), 2019 Jul, 29 (4) 513-529

Vewinger N, Huprich S, Seidmann L, Russo A, Alt F, Bender H, Sommer C, Samuel D, Lehmann N, Backes N, Roth L, Harter PN, Filipski K, Faber J & Paret C
IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients.
International journal of molecular sciences, 2019 Jun 21, 20 (12)

Mastrella G, Hou M, Li M, Stoecklein VM, Zdouc N, Volmar MNM, Miletic H, Reinhard S, Herold-Mende CC, Kleber S, Eisenhut K, Gargiulo G, Synowitz M, Vescovi AL, Harter PN, Penninger JM, Wagner E, Mittelbronn M, Bjerkvig R, Hambardzumyan D, Schüller U, Tonn JC, Radke J, Glass R & Kälin RE
Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma.
Cancer research, 2019 May 01, 79 (9) 2298-2313

Sundstrøm T, Prestegarden L, Azuaje F, Aasen SN, Røsland GV, Varughese JK, Bahador M, Bernatz S, Braun Y, Harter PN, Skaftnesmo KO, Ingham ES, Mahakian LM, Tam S, Tepper CG, Petersen K, Ferrara KW, Tronstad KJ, Lund-Johansen M, Beschorner R, Bjerkvig R & Thorsen F
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis.
Acta neuropathologica communications, 2019 Apr 10, 7 (1) 55

Forster MT, Baumgarten P, Gessler F, Maurer G, Senft C, Hattingen E, Seifert V, Harter PN & Franz K
Influence of pregnancy on glioma patients.
Acta neurochirurgica, 2019 Mar, 161 (3) 535-543

Foltyn M, Luger AL, Lorenz NI, Sauer B, Mittelbronn M, Harter PN, Steinbach JP & Ronellenfitsch MW
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.
British journal of cancer, 2019 Mar, 120 (5) 481-487

Bruns I, Sauer B, Burger MC, Eriksson J, Hofmann U, Braun Y, Harter PN, Luger AL, Ronellenfitsch MW, Steinbach JP & Rieger J
Disruption of peroxisome proliferator-activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells.
The Journal of biological chemistry, 2019 Mar 01, 294 (9) 3037-3050

Linder B, Weirauch U, Ewe A, Uhmann A, Seifert V, Mittelbronn M, Harter PN, Aigner A & Kögel D
Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model.
Cancers, 2019 Mar 08, 11 (3)

Eisemann T, Costa B, Harter PN, Wick W, Mittelbronn M, Angel P & Peterziel H
Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
Neuro-oncology, 2019 Feb 19, 21 (3) 326-336

Burger MC, Zhang C, Harter PN, Romanski A, Strassheimer F, Senft C, Tonn T, Steinbach JP & Wels WS
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Frontiers in immunology, 2019, 10 2683

Gessler F, Bernstock JD, Braczynski A, Lescher S, Baumgarten P, Harter PN, Mittelbronn M, Wu T, Seifert V & Senft C
Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Neurosurgery, 2019 Jan 01, 84 (1) 190-197

Wenger KJ, Hattingen E, Harter PN, Richter C, Franz K, Steinbach JP, Bähr O & Pilatus U
Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-hydroxyglutarate with 1 H-MRS.
NMR in biomedicine, 2019 Jan, 32 (1) e4027

2018

Sievers P, Stichel D, Hielscher T, Schrimpf D, Reinhardt A, Wefers AK, Reuss D, Jones DTW, Bewerunge-Hudler M, Hartmann C, Baumgarten P, Wirsching HG, Winther-Kristensen B, Brokinkel B, Ketter R, Idoate Gastearena MA, Lamszus K, Seiz-Rosenhagen M, Mawrin C, Harter PN, Felsberg J, Hänggi D, Herold-Mende C, Berghoff AS, Weller M, Pfister SM, Wick W, Reifenberger G, Preusser M, von Deimling A & Sahm F
Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p.
Acta neuropathologica, 2018 Dec, 136 (6) 975-978

Dudvarski Stanković N, Bicker F, Keller S, Jones DT, Harter PN, Kienzle A, Gillmann C, Arnold P, Golebiewska A, Keunen O, Giese A, von Deimling A, Bäuerle T, Niclou SP, Mittelbronn M, Ye W, Pfister SM & Schmidt MHH
EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumors.
EMBO molecular medicine, 2018 Sep, 10 (9)

Ronellenfitsch MW, Zeiner PS, Mittelbronn M, Urban H, Pietsch T, Reuter D, Senft C, Steinbach JP, Westphal M & Harter PN
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma.
Acta neuropathologica communications, 2018 Aug 21, 6 (1) 81

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W & Platten M
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Nature medicine, 2018 Aug, 24 (8) 1192-1203

Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching HG, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C & Sahm F
Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Acta neuropathologica, 2018 Jun, 135 (6) 955-963

Jennewein L, Bartsch G, Gust K, Kvasnicka HM, Haferkamp A, Blaheta R, Mittelbronn M, Harter PN & Mani J
Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors.
Oncology letters, 2018 Jun, 15 (6) 9852-9860

Eskilsson E, Røsland GV, Solecki G, Wang Q, Harter PN, Graziani G, Verhaak RGW, Winkler F, Bjerkvig R & Miletic H
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
Neuro-oncology, 2018 May 18, 20 (6) 743-752

Luger AL, Sauer B, Lorenz NI, Engel AL, Braun Y, Voss M, Harter PN, Steinbach JP & Ronellenfitsch MW
Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems.
International journal of molecular sciences, 2018 May 17, 19 (5)

Dubinski D, Won SY, Gessler F, Quick-Weller J, Behmanesh B, Bernatz S, Forster MT, Franz K, Plate KH, Seifert V, Harter PN & Senft C
Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma.
Journal of neuro-oncology, 2018 May, 137 (3) 503-510

Mäder L, Blank AE, Capper D, Jansong J, Baumgarten P, Wirsik NM, Zachskorn C, Ehlers J, Seifert M, Klink B, Liebner S, Niclou S, Naumann U, Harter PN & Mittelbronn M
Pericytes/vessel-associated mural cells (VAMCs) are the major source of key epithelial-mesenchymal transition (EMT) factors SLUG and TWIST in human glioma.
Oncotarget, 2018 May 08, 9 (35) 24041-24053

Groß A, Schulz C, Kolb J, Koster J, Wehner S, Czaplinski S, Khilan A, Rohrer H, Harter PN, Klingebiel T, Langer JD, Geerts D & Schulte D
Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma.
Cancer research, 2018 Apr 15, 78 (8) 1935-1947

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A & Pfister SM
DNA methylation-based classification of central nervous system tumours.
Nature, 2018 Mar 22, 555 (7697) 469-474

Zeiner PS, Zinke J, Kowalewski DJ, Bernatz S, Tichy J, Ronellenfitsch MW, Thorsen F, Berger A, Forster MT, Muller A, Steinbach JP, Beschorner R, Wischhusen J, Kvasnicka HM, Plate KH, Stefanović S, Weide B, Mittelbronn M & Harter PN
CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.
Acta neuropathologica communications, 2018 Mar 01, 6 (1) 18

Blasel S, Vorwerk R, Kiyose M, Mittelbronn M, Brunnberg U, Ackermann H, Voss M, Harter PN & Hattingen E
New MR perfusion features in primary central nervous system lymphomas: pattern and prognostic impact.
Journal of neurology, 2018 Mar, 265 (3) 647-658

Walter D, Harter PN, Battke F, Winkelmann R, Schneider M, Holzer K, Koch C, Bojunga J, Zeuzem S, Hansmann ML, Peveling-Oberhag J & Waidmann O
Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors.
Scientific reports, 2018 Feb 28, 8 (1) 3811

Eriksson JA, Wanka C, Burger MC, Urban H, Hartel I, von Renesse J, Harter PN, Mittelbronn M, Steinbach JP & Rieger J
Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma.
Journal of neurochemistry, 2018 Feb, 144 (4) 421-430

Ronellenfitsch MW, Oh JE, Satomi K, Sumi K, Harter PN, Steinbach JP, Felsberg J, Capper D, Voegele C, Durand G, McKay J, Le Calvez-Kelm F, Schittenhelm J, Klink B, Mittelbronn M & Ohgaki H
CASP9 germline mutation in a family with multiple brain tumors.
Brain pathology (Zurich, Switzerland), 2018 Jan, 28 (1) 94-102

Quick-Weller J, Tichy J, Harter PN, Tritt S, Baumgarten P, Bähr O, Dinc N, Behmanesh B, Weise L, Seifert V & Marquardt G
"Two is not enough" - Impact of the number of tissue samples obtained from stereotactic brain biopsies in suspected glioblastoma.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2018 Jan, 47 311-314

2017

Burger MC, Ronellenfitsch MW, Lorenz NI, Wagner M, Voss M, Capper D, Tzaridis T, Herrlinger U, Steinbach JP, Stoffels G, Langen KJ, Brandts C, Senft C, Harter PN & Bähr O
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.
Oncology reports, 2017 Dec, 38 (6) 3291-3296

Burger MC, Breuer S, Cieplik HC, Harter PN, Franz K, Bähr O & Steinbach JP
Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.
International journal of molecular sciences, 2017 Nov 20, 18 (11)

Bähr O, Gross S, Harter PN, Kirches E, Mawrin C, Steinbach JP & Mittelbronn M
ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors.
Oncology letters, 2017 Nov, 14 (5) 5443-5451

Thiepold AL, Lorenz NI, Foltyn M, Engel AL, Divé I, Urban H, Heller S, Bruns I, Hofmann U, Dröse S, Harter PN, Mittelbronn M, Steinbach JP & Ronellenfitsch MW
Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death.
Brain : a journal of neurology, 2017 Oct 01, 140 (10) 2623-2638

Ilina EI, Armento A, Sanchez LG, Reichlmeir M, Braun Y, Penski C, Capper D, Sahm F, Jennewein L, Harter PN, Zukunft S, Fleming I, Schulte D, Le Guerroué F, Behrends C, Ronellenfitsch MW, Naumann U & Mittelbronn M
Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux.
Oncotarget, 2017 Sep 15, 8 (40) 67567-67591

Torres-Odio S, Key J, Hoepken HH, Canet-Pons J, Valek L, Roller B, Walter M, Morales-Gordo B, Meierhofer D, Harter PN, Mittelbronn M, Tegeder I, Gispert S & Auburger G
Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation.
Journal of neuroinflammation, 2017 Aug 02, 14 (1) 154

Harter PN, Braun Y & Plate KH
Classification of meningiomas-advances and controversies.
Chinese clinical oncology, 2017 Jul, 6 (Suppl 1) S2

Gfroerer S, Theilen TM, Fiegel H, Harter PN, Mittelbronn M & Rolle U
Identification of intestinal ganglioneuromatosis leads to early diagnosis of MEN2B: role of rectal biopsy.
Journal of pediatric surgery, 2017 Jul, 52 (7) 1161-1165

Wenger KJ, Wagner M, You SJ, Franz K, Harter PN, Burger MC, Voss M, Ronellenfitsch MW, Fokas E, Steinbach JP & Bähr O
Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.
Oncology letters, 2017 Jul, 14 (1) 1141-1146

Bicker F, Vasic V, Horta G, Ortega F, Nolte H, Kavyanifar A, Keller S, Stankovic ND, Harter PN, Benedito R, Lutz B, Bäuerle T, Hartwig J, Baumgart J, Krüger M, Radyushkin K, Alberi L, Berninger B & Schmidt MHH
Neurovascular EGFL7 regulates adult neurogenesis in the subventricular zone and thereby affects olfactory perception.
Nature communications, 2017 Jun 28, 8 15922

Gessler F, Baumgarten P, Bernstock JD, Harter P, Lescher S, Senft C, Seifert V, Marquardt G & Weise L
Assessment of molecular markers demonstrates concordance between samples acquired via stereotactic biopsy and open craniotomy in both anaplastic astrocytomas and glioblastomas.
Journal of neuro-oncology, 2017 Jun, 133 (2) 399-407

Talasila KM, Røsland GV, Hagland HR, Eskilsson E, Flønes IH, Fritah S, Azuaje F, Atai N, Harter PN, Mittelbronn M, Andersen M, Joseph JV, Hossain JA, Vallar L, Noorden CJ, Niclou SP, Thorsen F, Tronstad KJ, Tzoulis C, Bjerkvig R & Miletic H
The angiogenic switch leads to a metabolic shift in human glioblastoma.
Neuro-oncology, 2017 Mar 01, 19 (3) 383-393

Behmanesh B, Setzer M, Konczalla J, Harter P, Quick-Weller J, Imoehl L, Franz K, Gessler F, Seifert V & Marquardt G
Management of Patients with Primary Intramedullary Spinal Cord Glioblastoma.
World neurosurgery, 2017 Feb, 98 198-202

2016

Weide B, Schäfer T, Martens A, Kuzkina A, Uder L, Noor S, Garbe C, Harter PN, Mittelbronn M & Wischhusen J
High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.
The Journal of investigative dermatology, 2016 Dec, 136 (12) 2444-2452

Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, Foerster S, Solecki G, Taxt T, Jirik R, Fritah S, Harter PN, Välk K, Al Hossain J, Joseph JV, Jahedi R, Saed HS, Piccirillo SG, Spiteri I, Leiss L, Euskirchen P, Graziani G, Daubon T, Lund-Johansen M, Enger PØ, Winkler F, Ritter CA, Niclou SP, Watts C, Bjerkvig R & Miletic H
EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Neuro-oncology, 2016 Dec, 18 (12) 1644-1655

Brucker DP, Maurer GD, Harter PN, Rieger J & Steinbach JP
FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death.
International journal of oncology, 2016 Dec, 49 (6) 2399-2410

Baumgarten P, Gessler F, Schittenhelm J, Skardelly M, Tews DS, Senft C, Dunst M, Imoehl L, Plate KH, Wagner M, Steinbach JP, Seifert V, Mittelbronn M & Harter PN
Brain invasion in otherwise benign meningiomas does not predict tumor recurrence.
Acta neuropathologica, 2016 Sep, 132 (3) 479-81

Devraj K, Poznanovic S, Spahn C, Schwall G, Harter PN, Mittelbronn M, Antoniello K, Paganetti P, Muhs A, Heilemann M, Hawkins RA, Schrattenholz A & Liebner S
BACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2016 Jul, 36 (7) 1281-94

Bougnaud S, Golebiewska A, Oudin A, Keunen O, Harter PN, Mäder L, Azuaje F, Fritah S, Stieber D, Kaoma T, Vallar L, Brons NH, Daubon T, Miletic H, Sundstrøm T, Herold-Mende C, Mittelbronn M, Bjerkvig R & Niclou SP
Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma.
Oncotarget, 2016 May 31, 7 (22) 31955-71

Zhang C, Burger MC, Jennewein L, Genßler S, Schönfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP & Wels WS
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Journal of the National Cancer Institute, 2016 May, 108 (5)

Winter L, Türk M, Harter PN, Mittelbronn M, Kornblum C, Norwood F, Jungbluth H, Thiel CT, Schlötzer-Schrehardt U & Schröder R
Downstream effects of plectin mutations in epidermolysis bullosa simplex with muscular dystrophy.
Acta neuropathologica communications, 2016 Apr 27, 4 (1) 44

Jennewein L, Ronellenfitsch MW, Antonietti P, Ilina EI, Jung J, Stadel D, Flohr LM, Zinke J, von Renesse J, Drott U, Baumgarten P, Braczynski AK, Penski C, Burger MC, Theurillat JP, Steinbach JP, Plate KH, Dikic I, Fulda S, Brandts C, Kögel D, Behrends C, Harter PN & Mittelbronn M
Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas.
Oncotarget, 2016 Apr 12, 7 (15) 20016-32

Bartsch G, Jennewein L, Harter PN, Antonietti P, Blaheta RA, Kvasnicka HM, Kögel D, Haferkamp A, Mittelbronn M & Mani J
Autophagy-associated proteins BAG3 and p62 in testicular cancer.
Oncology reports, 2016 Mar, 35 (3) 1629-35

Baumgarten P, Blank AE, Franz K, Hattingen E, Dunst M, Zeiner P, Hoffmann K, Bähr O, Mäder L, Goeppert B, Machein M, Seifert V, Steinbach JP, Plate KH, Harter PN & Mittelbronn M
Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Neuro-oncology, 2016 Feb, 18 (2) 173-83

Niyazi M, Harter PN, Hattingen E, Rottler M, von Baumgarten L, Proescholdt M, Belka C, Lauber K & Mittelbronn M
Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
Oncotarget, 2016 Jan 19, 7 (3) 2313-28

Blasel S, Zagorcic A, Jurcoane A, Bähr O, Wagner M, Harter PN & Hattingen E
Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence.
Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2016, 26 (1) 116-23

Braczynski AK, Harter PN, Zeiner PS, Drott U, Tews DS, Preusse C, Penski C, Dunst M, Weis J, Stenzel W & Mittelbronn M
C5b-9 deposits on endomysial capillaries in non-dermatomyositis cases.
Neuromuscular disorders : NMD, 2016, 26 (4-5) 283-91

Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, Di Tacchio M, Sommer K, Baumgarten P, Bähr O, Steinbach JP, Trojan J, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C, Schittenhelm J, Frueh JT, Ullrich E, Mittelbronn M, Plate KH & Reiss Y
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.
EMBO molecular medicine, 2016 Jan 01, 8 (1) 39-57

2015

Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B & Mittelbronn M
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Oncotarget, 2015 Dec 01, 6 (38) 40836-49

Sundstrøm T, Espedal H, Harter PN, Fasmer KE, Skaftnesmo KO, Horn S, Hodneland E, Mittelbronn M, Weide B, Beschorner R, Bender B, Rygh CB, Lund-Johansen M, Bjerkvig R & Thorsen F
Melanoma brain metastasis is independent of lactate dehydrogenase A expression.
Neuro-oncology, 2015 Oct, 17 (10) 1374-85

Seo SW, Koeppen M, Bonney S, Gobel M, Thayer M, Harter PN, Ravid K, Eltzschig HK, Mittelbronn M, Walker L & Eckle T
Differential Tissue-Specific Function of Adora2b in Cardioprotection.
Journal of immunology (Baltimore, Md. : 1950), 2015 Aug 15, 195 (4) 1732-43

Zeiner PS, Preusse C, Blank AE, Zachskorn C, Baumgarten P, Caspary L, Braczynski AK, Weissenberger J, Bratzke H, Reiß S, Pennartz S, Winkelmann R, Senft C, Plate KH, Wischhusen J, Stenzel W, Harter PN & Mittelbronn M
MIF Receptor CD74 is Restricted to Microglia/Macrophages, Associated with a M1-Polarized Immune Milieu and Prolonged Patient Survival in Gliomas.
Brain pathology (Zurich, Switzerland), 2015 Jul, 25 (4) 491-504

Thiepold AL, Luger S, Wagner M, Filmann N, Ronellenfitsch MW, Harter PN, Braczynski AK, Dützmann S, Hattingen E, Steinbach JP, Senft C, Rieger J & Bähr O
Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma.
Oncotarget, 2015 Jun 10, 6 (16) 14537-44

Doberstein K, Harter PN, Haberkorn U, Bretz NP, Arnold B, Carretero R, Moldenhauer G, Mittelbronn M & Altevogt P
Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT.
International journal of cancer, 2015 Mar 01, 136 (5) E326-39

Zinke J, Schneider FT, Harter PN, Thom S, Ziegler N, Toftgård R, Plate KH & Liebner S
β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma.
Molecular cancer, 2015 Feb 03, 14 (1) 17

Blank AE, Baumgarten P, Zeiner P, Zachskorn C, Löffler C, Schittenhelm J, Czupalla CJ, Capper D, Plate KH, Harter PN & Mittelbronn M
Tumour necrosis factor receptor superfamily member 9 (TNFRSF9) is up-regulated in reactive astrocytes in human gliomas.
Neuropathology and applied neurobiology, 2015 Feb, 41 (2) e56-67

Harter PN, Baumgarten P, Zinke J, Schilling K, Baader S, Hartmetz AK, Schittenhelm J, Beschorner R, Liebner S, Schulte D, Plate KH, Gutwein P, Korshunov A, Pfister SM, Jones DT, Doberstein K & Mittelbronn M
Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas.
Neuropathology and applied neurobiology, 2015 Feb, 41 (2) 165-79

Michaelis M, Agha B, Rothweiler F, Löschmann N, Voges Y, Mittelbronn M, Starzetz T, Harter PN, Abhari BA, Fulda S, Westermann F, Riecken K, Spek S, Langer K, Wiese M, Dirks WG, Zehner R, Cinatl J, Wass MN & Cinatl J
Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.
Scientific reports, 2015 Feb 03, 5 8202

Braczynski AK, Vlaho S, Müller K, Wittig I, Blank AE, Tews DS, Drott U, Kleinle S, Abicht A, Horvath R, Plate KH, Stenzel W, Goebel HH, Schulze A, Harter PN, Kieslich M & Mittelbronn M
ATP synthase deficiency due to TMEM70 mutation leads to ultrastructural mitochondrial degeneration and is amenable to treatment.
BioMed research international, 2015, 2015 462592

Tichy J, Zinke J, Bunz B, Meyermann R, Harter PN & Mittelbronn M
Expression Profile of Sonic Hedgehog Pathway Members in the Developing Human Fetal Brain.
BioMed research international, 2015, 2015 494269

Harter PN, Jennewein L, Baumgarten P, Ilina E, Burger MC, Thiepold AL, Tichy J, Zörnig M, Senft C, Steinbach JP, Mittelbronn M & Ronellenfitsch MW
Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors.
PloS one, 2015, 10 (5) e0127123

Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter PN, Mittelbronn M, Bähr O, Weyerbrock A, Stuhr L, Miletic H, Sakariassen PØ, Stieber D, Rygh CB, Lund-Johansen M, Zheng L, Gottlieb E, Niclou SP & Bjerkvig R
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas.
Acta neuropathologica, 2015 Jan, 129 (1) 115-31

2014

Balermpas P, Rödel F, Liberz R, Oppermann J, Wagenblast J, Ghanaati S, Harter PN, Mittelbronn M, Weiss C, Rödel C & Fokas E
Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences.
British journal of cancer, 2014 Oct 14, 111 (8) 1509-18

Risolino M, Mandia N, Iavarone F, Dardaei L, Longobardi E, Fernandez S, Talotta F, Bianchi F, Pisati F, Spaggiari L, Harter PN, Mittelbronn M, Schulte D, Incoronato M, Di Fiore PP, Blasi F & Verde P
Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-β-SMAD3 pathway in non-small cell lung adenocarcinoma.
Proceedings of the National Academy of Sciences of the United States of America, 2014 Sep 09, 111 (36) E3775-84

Bähr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, Rieger J, Steinbach JP & Hattingen E
Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma.
Neurology, 2014 Jul 15, 83 (3) 227-34

Pantazis G, Harter PN, Capper D, Kohlhof P, Mittelbronn M & Schittenhelm J
The embryonic stem cell factor UTF1 serves as a reliable diagnostic marker for germinomas.
Pathology, 2014 Apr, 46 (3) 225-9

Quick J, Gessler F, Dützmann S, Hattingen E, Harter PN, Weise LM, Franz K, Seifert V & Senft C
Benefit of tumor resection for recurrent glioblastoma.
Journal of neuro-oncology, 2014 Apr, 117 (2) 365-72

Baumgarten P, Harter PN, Tönjes M, Capper D, Blank AE, Sahm F, von Deimling A, Kolluru V, Schwamb B, Rabenhorst U, Starzetz T, Kögel D, Rieker RJ, Plate KH, Ohgaki H, Radlwimmer B, Zörnig M & Mittelbronn M
Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.
Neuropathology and applied neurobiology, 2014 Feb, 40 (2) 205-16

Weise LM, Harter PN, Eibach S, Braczynski AK, Dunst M, Rieger J, Bähr O, Hattingen E, Steinbach JP, Plate KH, Seifert V & Mittelbronn M
Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies.
Stereotactic and functional neurosurgery, 2014, 92 (3) 129-39

Fischer S, Ronellenfitsch MW, Thiepold AL, Harter PN, Reichert S, Kögel D, Paschke R, Mittelbronn M, Weller M, Steinbach JP, Fulda S & Bähr O
Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid.
PloS one, 2014, 9 (4) e94921

Harter PN, Zinke J, Scholz A, Tichy J, Zachskorn C, Kvasnicka HM, Goeppert B, Delloye-Bourgeois C, Hattingen E, Senft C, Steinbach JP, Plate KH, Mehlen P, Schulte D & Mittelbronn M
Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases.
PloS one, 2014, 9 (3) e92311

Mittelbronn M, Baumgarten P, Harter PN & Plate KH
Analysis of cerebral angiogenesis in human glioblastomas.
Methods in molecular biology (Clifton, N.J.), 2014, 1135 187-203

2013

Thorsen F, Fite B, Mahakian LM, Seo JW, Qin S, Harrison V, Johnson S, Ingham E, Caskey C, Sundstrøm T, Meade TJ, Harter PN, Skaftnesmo KO & Ferrara KW
Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases.
Journal of controlled release : official journal of the Controlled Release Society, 2013 Dec 28, 172 (3) 812-22

Harter PN, Dützmann S, Drott U, Zachskorn C, Hattingen E, Capper D, Gessler F, Senft C, Seifert V, Plate KH, Kögel D & Mittelbronn M
Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model.
Neuropathology : official journal of the Japanese Society of Neuropathology, 2013 Oct, 33 (5) 515-25

Goeppert B, Schmidt CR, Geiselhart L, Dutruel C, Capper D, Renner M, Vogel MN, Zachskorn C, Zinke J, Campos B, Schmezer P, Popanda O, Wick W, Weller M, Meyermann R, Schittenhelm J, Harter PN, Simon P, Weichert W, Schirmacher P, Plass C & Mittelbronn M
Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation.
Journal of neuropathology and experimental neurology, 2013 Oct, 72 (10) 933-41

Baumgarten P, Brokinkel B, Zinke J, Zachskorn C, Ebel H, Albert FK, Stummer W, Plate KH, Harter PN, Hasselblatt M & Mittelbronn M
Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas.
Histology and histopathology, 2013 Sep, 28 (9) 1157-66

Blasel S, Jurcoane A, Bähr O, Weise L, Harter PN & Hattingen E
MR perfusion in and around the contrast-enhancement of primary CNS lymphomas.
Journal of neuro-oncology, 2013 Aug, 114 (1) 127-34

Nikolic I, Stankovic ND, Bicker F, Meister J, Braun H, Awwad K, Baumgart J, Simon K, Thal SC, Patra C, Harter PN, Plate KH, Engel FB, Dimmeler S, Eble JA, Mittelbronn M, Schäfer MK, Jungblut B, Chavakis E, Fleming I & Schmidt MHH
EGFL7 ligates αvβ3 integrin to enhance vessel formation.
Blood, 2013 Apr 11, 121 (15) 3041-50

Bonney S, Hughes K, Harter PN, Mittelbronn M, Walker L & Eckle T
Cardiac period 2 in myocardial ischemia: clinical implications of a light dependent protein.
The international journal of biochemistry & cell biology, 2013 Mar, 45 (3) 667-71

Enzmann G, Mysiorek C, Gorina R, Cheng YJ, Ghavampour S, Hannocks MJ, Prinz V, Dirnagl U, Endres M, Prinz M, Beschorner R, Harter PN, Mittelbronn M, Engelhardt B & Sorokin L
The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury.
Acta neuropathologica, 2013 Mar, 125 (3) 395-412

Doberstein K, Steinmeyer N, Hartmetz AK, Eberhardt W, Mittelbronn M, Harter PN, Juengel E, Blaheta R, Pfeilschifter J & Gutwein P
MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients.
Neoplasia (New York, N.Y.), 2013 Feb, 15 (2) 218-30

Luger S, Harter PN, Mittelbronn M, Wagner M & Foerch C
Brain stem infarction associated with familial Mediterranean fever and central nervous system vasculitis.
Clinical and experimental rheumatology, 2013, 31 (3 Suppl 77) 93-5

2012

Höring E, Harter PN, Seznec J, Schittenhelm J, Bühring HJ, Bhattacharyya S, von Hattingen E, Zachskorn C, Mittelbronn M & Naumann U
The "go or grow" potential of gliomas is linked to the neuropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress.
Acta neuropathologica, 2012 Jul, 124 (1) 83-97

Koeppen M, Harter PN, Bonney S, Bonney M, Reithel S, Zachskorn C, Mittelbronn M & Eckle T
Adora2b signaling on bone marrow derived cells dampens myocardial ischemia-reperfusion injury.
Anesthesiology, 2012 Jun, 116 (6) 1245-57

Podlech O, Harter PN, Mittelbronn M, Pöschel S & Naumann U
Fermented mistletoe extract as a multimodal antitumoral agent in gliomas.
Evidence-based complementary and alternative medicine : eCAM, 2012, 2012 501796

2011

Scholz A, Lang V, Henschler R, Czabanka M, Vajkoczy P, Chavakis E, Drynski J, Harter PN, Mittelbronn M, Dumont DJ, Plate KH & Reiss Y
Angiopoietin-2 promotes myeloid cell infiltration in a β₂-integrin-dependent manner.
Blood, 2011 Nov 03, 118 (18) 5050-9

Reichert S, Rödel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M, Kaina B & Rödel F
Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011 Oct, 101 (1) 51-8

Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C, Harter PN, Weller M & Wischhusen J
Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression.
Acta neuropathologica, 2011 Sep, 122 (3) 353-65

Berger A, Reitter A, Harter PN, Buxmann H, Allwinn R, Louwen F & Doerr HW
Problems and challenges in the diagnosis of vertical infection with human cytomegalovirus (CMV): lessons from two accidental cases.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2011 Aug, 51 (4) 285-8

Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, Mueller-Klieser W, Steinbach JP & Rieger J
Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy.
BMC cancer, 2011 Jul 26, 11 315

Schuss P, Ulrich CT, Harter PN, Tews DS, Seifert V & Franz K
Gliosarcoma with bone infiltration and extracranial growth: case report and review of literature.
Journal of neuro-oncology, 2011 Jul, 103 (3) 765-70

Schittenhelm J, Simon P, Harter PN, Zachskorn C, Schlaszus H, Röttger F, Winkels M, Weller M, Meyermann R & Mittelbronn M
CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms.
Histopathology, 2011 Apr, 58 (5) 739-49

Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A & von Deimling A
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Acta neuropathologica, 2011 Feb, 121 (2) 241-52

2010

Harter PN, Bunz B, Dietz K, Hoffmann K, Meyermann R & Mittelbronn M
Spatio-temporal deleted in colorectal cancer (DCC) and netrin-1 expression in human foetal brain development.
Neuropathology and applied neurobiology, 2010 Dec, 36 (7) 623-35

Dützmann S, Gessler F, Harter PN, Gerlach R, Mittelbronn M, Seifert V & Kögel D
The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas.
Cell adhesion & migration, 2010, 4 (4) 515-22

2009

Mittelbronn M, Harter P, Warth A, Lupescu A, Schilbach K, Vollmann H, Capper D, Goeppert B, Frei K, Bertalanffy H, Weller M, Meyermann R, Lang F & Simon P
EGR-1 is regulated by N-methyl-D-aspartate-receptor stimulation and associated with patient survival in human high grade astrocytomas.
Brain pathology (Zurich, Switzerland), 2009 Apr, 19 (2) 195-204

2007

Mittelbronn M, Simon P, Löffler C, Capper D, Bunz B, Harter P, Schlaszus H, Schleich A, Tabatabai G, Goeppert B, Meyermann R, Weller M & Wischhusen J
Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells.
Journal of neuroimmunology, 2007 Sep, 189 (1-2) 50-8